JOHNSON & JOHNSON

JNJNYSE

Pharmaceutical PreparationsCIK 0000200406Live· source checked 3m oldlatest filing 2026-07-28

As-filed data from SEC EDGAR (US-government public domain). No market quotes on this page — filings and fundamentals only.

The information on this page is market data and educational analysis, not financial advice. Past on-chain activity does not guarantee future results. Always do your own research.

Annual fundamentals — as filed

Revenue

$94.2B

FY2025 · period ended 2025-12-28 · 10-K · SEC EDGAR

Net income

$26.8B

FY2025 · period ended 2025-12-28 · 10-K · SEC EDGAR

Total assets

$199.2B

FY2025 · period ended 2025-12-28 · 10-K · SEC EDGAR

Total liabilities

$117.7B

FY2025 · period ended 2025-12-28 · 10-K · SEC EDGAR

Recent filings

8-Kfiled 2026-07-28 · period 2026-07-27View on SEC.gov
10-Qfiled 2026-07-23 · period 2026-06-28View on SEC.gov
144filed 2026-07-20View on SEC.gov
8-Kfiled 2026-07-15 · period 2026-07-15View on SEC.gov
11-Kfiled 2026-06-25 · period 2025-12-31View on SEC.gov

Insider forms (3 / 4 / 5)

Statements of beneficial ownership filed by officers, directors and 10%+ owners. A filing documents a reported change — it is not a buy or sell signal.

Form 4filed 2026-07-21View on SEC.gov
Form 4filed 2026-06-12View on SEC.gov
Form 4filed 2026-06-11View on SEC.gov
Form 4filed 2026-06-11View on SEC.gov
Form 4filed 2026-06-11View on SEC.gov

Source: SEC EDGAR, as-filed documents (public domain). Figures are annual XBRL facts from the latest 10-K; no adjustments applied. Educational information only — not financial advice.